THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS

被引：0
|
作者：
Suboticki, T. [1 ]
Cokic, B. Beleslin [2 ]
Djikic, D. [1 ]
Mojsilovic, S. [3 ]
Sefer, D. [4 ]
Bjelica, S. [3 ]
Santibanez, J. [3 ]
Cokic, V. [3 ]
机构：
[1] Univ Belgrade, Inst Med Res, Lab Neuroendocrinol, Belgrade, Serbia
[2] Clin Ctr Serbia, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia
[3] Univ Belgrade, Inst Med Res, Lab Expt Hematol, Belgrade, Serbia
[4] Clin Ctr Serbia, Clin Hematol, Belgrade, Serbia
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1308
引用
收藏
页码：536 / 537
页数：2
相关论文
共 50 条
  • [1] Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms
    Thomas, Sally
    Fisher, Katherine
    Snowden, John
    Danson, Sarah
    Brown, Stephen
    Zeidler, Martin
    LANCET, 2015, 385 : 98 - 98
  • [2] JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
    O'Sullivan, Jennifer M.
    Harrison, Claire N.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 451 (0C) : 71 - 79
  • [3] Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
    Cokic, Vladan P.
    Mitrovic-Ajtic, Olivera
    Beleslin-Cokic, Bojana B.
    Markovic, Dragana
    Buac, Marijana
    Diklic, Milos
    Kraguljac-Kurtovic, Nada
    Damjanovic, Svetozar
    Milenkovic, Pavle
    Gotic, Mirjana
    Raj, Puri K.
    MEDIATORS OF INFLAMMATION, 2015, 2015
  • [4] Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
    Hao, Xing
    Xing, Wen
    Yuan, Jiajia
    Wang, Yingshao
    Bai, Jiaojiao
    Bai, Jie
    Zhou, Yuan
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 610 - 620
  • [5] Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
    Xing Hao
    Wen Xing
    Jiajia Yuan
    Yingshao Wang
    Jiaojiao Bai
    Jie Bai
    Yuan Zhou
    Investigational New Drugs, 2020, 38 : 610 - 620
  • [6] Biological aspects of JAK/STAT signaling in BCR-ABL-negative myeloproliferative neoplasms
    Mosca, Matthieu
    Vertenoeil, Gaelle
    Toppaldoddi, Katte Rao
    Plo, Isabelle
    Vainchenker, William
    BULLETIN DU CANCER, 2016, 103 (06) : S16 - S28
  • [7] Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
    Hobbs, Gabriela S.
    Somasundara, Amritha Varshini Hanasoge
    Kleppe, Maria
    Litvin, Rivka
    Arcila, Maria
    Ahn, Jihae
    McKenney, Anna Sophia
    Knapp, Kristina
    Ptashkin, Ryan
    Weinstein, Howard
    Heinemann, Murk-Hein
    Francis, Jasmine
    Chanel, Suzanne
    Berman, Ellin
    Mauro, Michael
    Tallman, Martin S.
    Heaney, Mark L.
    Levine, Ross L.
    Rampal, Raajit K.
    HAEMATOLOGICA, 2018, 103 (01)
  • [8] Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy
    Pasquier, Florence
    Cabagnols, Xenia
    Secardin, Lise
    Plo, Isabelle
    Vainchenker, Williai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S23 - S35
  • [9] JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
    Maslah, Nabih
    Roux, Blandine
    Kaci, Nina
    Verger, Emmanuelle
    De Oliveira, Rafael Daltro
    Pasquer, Helene
    Gauthier, Nicolas
    Soret, Juliette
    Ganesan, Saravanan
    Gou, Panhong
    Ling, Frank
    Parquet, Nathalie
    Vainchenker, William
    Raffoux, Emmanuel
    Padua, Rose Ann
    Giraudier, Stephane
    Puissant, Alexandre
    Lobry, Camille
    Kiladjian, Jean-Jacques
    Cassinat, Bruno
    Benajiba, Lina
    BLOOD, 2022, 140
  • [10] The JAK/STAT signaling pathway
    Touw, IP
    MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION, 2000, 316 : 193 - 199
12345